Try our beta test site
Trial record 1 of 1 for:    NCT01623349
Previous Study | Return to List | Next Study

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Novartis
AstraZeneca
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01623349
First received: June 7, 2012
Last updated: March 22, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)